(Q34495874)

2 August 2017

12 references

13 March 2019

17 June 2019

30 June 2019

1 August 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

27 November 2019

13 December 2019

1 February 2021

28 October 2022

Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety (English)

1 reference

2 August 2017

10 references

13 March 2019

17 June 2019

30 June 2019

1 August 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

27 November 2019

13 December 2019

tumor necrosis factor

2 references

1 August 2019

1 February 2021

1 reference

1 October 2019

1 reference

7 November 2019

macromolecular substance

1 reference

16 November 2019

1 reference

20 November 2019

1 reference

27 November 2019

1 reference

13 December 2019

Philip J Mease

1

1 reference

PubMed ID

20871129

2 August 2017

language of work or name

1 reference

25 September 2010

1 reference

PubMed ID

20871129

2 August 2017

1 February 2011

12 references

13 March 2019

17 June 2019

30 June 2019

1 August 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

27 November 2019

13 December 2019

1 February 2021

28 October 2022

13 references

2 August 2017

13 March 2019

17 June 2019

30 June 2019

1 August 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

27 November 2019

13 December 2019

1 February 2021

28 October 2022

50

1 reference

2 August 2017

2

1 reference

2 August 2017

261-270

1 reference

Creative Commons Attribution-NonCommercial 2.5 Generic

2 August 2017

12 references

13 March 2019

17 June 2019

30 June 2019

1 August 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

27 November 2019

13 December 2019

1 February 2021

on focus list of Wikimedia project

28 October 2022

ScienceSource

0 references

cites work

Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

The Stanford Health Assessment Questionnaire: dimensions and practical applications

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021948

Self-reported fatigue in rheumatoid arthritis. A pilot study

27 October 2018

1 reference

12 December 2020

Minimum important difference between patients with rheumatoid arthritis: the patient's perspective

1 reference

12 December 2020

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents

1 reference

12 December 2020

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

12 December 2020

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis

1 reference

12 December 2020

Measurement of patient outcome in arthritis

1 reference

12 December 2020

10.1093/RHEUMATOLOGY/KEQ285

Identifiers

DOI

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

PubMed ID

20871129